Wells Fargo Downgrades Tokai Pharmaceuticals (TKAI) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
BMO Capital Downgrades Tokai Pharmaceuticals (TKAI) to Market Perform
July 26, 2016 10:44 AM EDTBMO Capital downgraded Tokai Pharmaceuticals (NASDAQ: TKAI) from Outperform to Market Perform with a price target of $2.00.
For an analyst ratings summary and ratings history on Tokai Pharmaceuticals click here. For more ratings news on Tokai Pharmaceuticals click here.
Shares of Tokai Pharmaceuticals closed at $5.20 yesterday.
... MoreBMO Capital Downgrades Tokai Pharmaceuticals (TKAI) to Market Perform
July 26, 2016 10:43 AM EDTBMO Capital downgraded Tokai Pharmaceuticals (NASDAQ: TKAI) from Outperform to Market Perform with a price target of $1.70 (from $11.00) following the discontinuation of ARMOR3-SV.
Analyst Do Kim commented, "We are downgrading Tokai (TKAI) shares to Market Perform from Outperform, following the... More
Stifel Downgrades Tokai Pharmaceuticals (TKAI) to Hold
July 26, 2016 9:45 AM EDTStifel downgraded Tokai Pharmaceuticals (NASDAQ: TKAI) from Buy to Hold after ARMOR3 stopped.
Analyst Thomas Shrader commented, "The ARMOR3 DMC has informed Tokai that the trial is unlikely to reach its rPFS endpoint (ruling of futility). Essentially no other data was... More
Janney Montgomery Scott Downgrades Tokai Pharmaceuticals (TKAI) to Neutral
July 26, 2016 8:50 AM EDTJanney Montgomery Scott downgraded Tokai Pharmaceuticals (NASDAQ: TKAI) from Buy to Neutral with a price target of $2.00 (from $12.00).
For an analyst ratings summary and ratings history on Tokai Pharmaceuticals click here. For more ratings news on Tokai Pharmaceuticals click here.
Shares of Tokai Pharmaceuticals closed at $5.20 yesterday.
... MoreTokai Pharma (TKAI) will resume trading at 7:30am ET
July 26, 2016 7:20 AM EDTTokai Pharma (NASDAQ: TKAI) will resume trading at 7:30am EDT.
... MoreTokai Pharma (TKAI) to Cease ARMOR3-SV Clinical Trial
July 26, 2016 7:05 AM EDTTokai Pharmaceuticals Inc. (Nasdaq: TKAI) announced that it plans to discontinue the ARMOR3-SV clinical trial, the companys pivotal Phase 3 study comparing galeterone to enzalutamide in treatment-naïve metastatic castration-resistant prostate cancer (mCRPC) patients whose prostate tumors express AR-V7, following the recommendation made yesterday by the trials independent Data Monitoring Committee (DMC).
Based on a review of all safety and efficacy data, the DMC determined that the ARMOR3-SV trial will likely not succeed in meeting its primary endpoint of demonstrating an improvement in radiographic progression-free survival (rPFS) for galeterone... More
Tokai Pharma (TKAI) trading halted with news pending
July 26, 2016 6:55 AM EDTTokai Pharma (NASDAQ: TKAI) trading halted with news pending.
... More